Q3 2021 Bergenbio ASA Earnings Call Transcript
Yes. So good morning, everyone, and welcome to the Q3 2021 Report Highlights and the Financial for BerGenBio. Today, the management team -- or this part of the management team will be present for the presentation. It will be myself. I'm Martin Olin, the CEO of BerGenBio; Rune Skeie, our CFO; and Nigel McCracken, our CSO.
Yes. So just to remind everyone about the formalities, the forward-looking statement disclaimer. I wouldn't spend too much time on that.
So the agenda for today is that I will go through the Q3 and the recent highlights. I'll touch a little bit upon the update on our AXL inhibitor programs, specifically bemcentinib and its potential in AML, non-small cell lung cancer and COVID. I'll also give an update on tilvestamab. Rune will take you through the financial report, and we will summarize the position of BerGenBio at the end of today's meeting.
So summarizing the Q3 recent highlights. As some of you may have noticed, we have presented very exciting data in non-small cell lung cancer, specifically for patients harboring the STK11
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
